Zhuge Zhang

Capital Medical University, Peping, Beijing, China

Are you Zhuge Zhang?

Claim your profile

Publications (2)8.65 Total impact

  • Li Li · Ming Zhao · Wenhao Li · Yuji Wang · Zhuge Zhang · Ran An · Shiqi Peng
    [Show abstract] [Hide abstract]
    ABSTRACT: Target cancer therapy could be achieved by self-complexation and complexation between β-carboline–β-cyclodextrin and doxorubicin. Self-complex/complex was formed at neutral normal tissues. It converted to complex at acidic tumor tissue. Thus, doxorubicin could be targeted and carried to tumor cells. The survival of mice had been improved.
    No preview · Article · Aug 2012 · Medicinal Chemistry Communication
  • [Show abstract] [Hide abstract]
    ABSTRACT: The modification of 3S-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (THIQA) with β-cyclodextrin (β-CD) provides an oral antithrombotic agent, 6-(3'S-isoquinoline-3'-carboxylaminoethylamino)-6-deoxy-β-CD (THIQA-β-CD). In aqueous solution THIQA-β-CD undergoes intermolecular inclusion complexation and forms pH-dependent nanostructures. The morphological feature of THIQA-β-CD is a nanocloud consisting of numerous particles that are 5 nm-6 nm in diameter at pH 3.0. The nanocloud switches to a nanorod ranging from 100 nm to 385 nm in length at pH 7.2, then to nanowires of 50 nm to 530 nm in length at pH 10.1. THIQA-β-CD, which has unusual nanostructures, offers enhanced stability in blood. Inhibition of thrombin-induced platelet aggregation in vitro and demonstrated antithrombotic efficacy in vivo. This investigation demonstrated that the modification of THIQA with β-CD is a promising approach for clinical therapy of thrombus disease. The pH-dependent nanostructures of conjugate provide the desired in vivo antithrombotic activity and in vitro stability in blood. FROM THE CLINICAL EDITOR: This study a demonstrates that the modification of 3S-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (THIQA) with beta-cyclodextrin, which leads to pH dependent nanostructure formation, is a promising approach for clinical therapy of thrombotic disease.
    No preview · Article · Jan 2012 · Nanomedicine: nanotechnology, biology, and medicine